Antibody-mediated endothelial cell damage via nitric oxide.

abstract：:Agomelatine markedly differs from other classes of antidepressant drugs: its primary molecular targets in vivo are the melatonin MT(1) and MT(2) receptors, where it acts as a potent agonist, and the 5-HT(2C) receptors, where it exerts clear-cut antagonist properties. Agomelatine across a wide range of clinical trials ...

journal_title：Current pharmaceutical design

authors： Bourin M,Prica C

更新日期：2009-01-01 00:00:00

abstract：:Although the cause of Crohn's disease remains unknown considerable progress has been made in recent years to unravel the pathogenesis of the inflammatory processes seen in chronic idiopathic inflammatory bowel diseases (IBD). Th-1 lymphocytes seem to orchestrate the inflammation through the production of pro-inflammat...

journal_title：Current pharmaceutical design

authors： D'Haens G

更新日期：2003-01-01 00:00:00

abstract：:Head and neck cancer refers to a group of malignancies that affects the epithelium of the upper aereodigestive tract, primarily the lip and mouth, pharynx and larynx. Head and neck cancer is strongly associated with tobacco smoking, alcohol consumption and betel nut chewing, and indeed a reduction in the exposure to t...

journal_title：Current pharmaceutical design

authors： Forster M,Mendes R,Fedele S

更新日期：2012-01-01 00:00:00

abstract：BACKGROUND:Neglected tropical diseases (NTDs) represent a serious problem in a number of countries around the world and especially in Africa and South America, affecting mostly the poor population which has limited access to the healthcare system. The drugs currently used for the treatment of NTDs are dated many decade...

journal_title：Current pharmaceutical design

authors： Chazapi E,Magoulas GE,Prousis KC,Calogeropoulou T

更新日期：2020-12-09 00:00:00

abstract：:DNA methyltransferase (DNMT) and histone deacetylase are key enzymes mediating the epigenetic regulation of gene expression. DNA hypermethylation and/or histone deacetylation in promoter regions is often associated with downregulation or silencing of transcription. Epigenetic silencing of tumor suppressor genes plays ...

journal_title：Current pharmaceutical design

authors： Xu S,Ren J,Chen HB,Wang Y,Liu Q,Zhang R,Jiang SW,Li J

更新日期：2014-01-01 00:00:00

abstract：:Genetic variation in the receptors and other intracellular targets that mediate the pharmacodynamic effects of drugs can affect therapeutic outcomes. However, at present greater knowledge is available concerning the extent of gene variation in drug metabolizing enzymes that determine drug pharmacokinetics and, in turn...

journal_title：Current pharmaceutical design

authors： Crettol S,Petrovic N,Murray M

更新日期：2010-01-01 00:00:00

abstract：BACKGROUND & AIMS:Nowadays, the world is facing a common problem that the population aging process is accelerating. How to delay metabolic disorders in middle-aged and elderly people, has become a hot scientific and social issue worthy of attention. The liver plays an important role in lipid metabolism, and abnormal li...

journal_title：Current pharmaceutical design

authors： Su H,Liu D,Shao J,Li Y,Wang X,Gao Q

更新日期：2020-01-01 00:00:00

abstract：:Drug design based on the structure of specific enzymes playing a role in carcinogenesis, e.g. tyrosine kinases, has been successful at identifying novel effective anticancer drugs. In contrast, no success has been achieved in drug design attempts, in which transcription factors or DNA-transcription factor complexes in...

journal_title：Current pharmaceutical design

authors： D'Incalci M,Brunelli D,Marangon E,Simone M,Tavecchio M,Gescher A,Mantovani R

更新日期：2007-01-01 00:00:00

abstract：:Exercise and sports activity are beneficial both physically and psychologically but excessive exercise may have adverse physiological and psychological effects. There are methodological issues in the definition, diagnosis and etiology of exercise addiction. Several questionnaires and diagnostic tools have been develop...

journal_title：Current pharmaceutical design

authors： Weinstein A,Weinstein Y

更新日期：2014-01-01 00:00:00

abstract：:Tumour resistance to anticancer agents remains a challenge in oncological practice, because it results in exposure to toxicities, unnecessary costs and, most importantly, delay of a potentially more effective treatment. Drug uptake by tumours may be impaired by several resistance pathways. Reasons for primary resistan...

journal_title：Current pharmaceutical design

authors： van der Veldt AA,Luurtsema G,Lubberink M,Lammertsma AA,Hendrikse NH

更新日期：2008-01-01 00:00:00

abstract：:After years of pre-clinical and clinical testing monoclonal antibodies (mAbs) finally offer new therapeutic choices for patients with haematological and solid malignancies both as unconjugated antibody and as vectors to target radionuclides in radioimmunotherapy (RIT). In recent years some of the most exciting clinica...

journal_title：Current pharmaceutical design

authors： Illidge TM,Brock S

更新日期：2000-09-01 00:00:00

abstract：:The intestinal epithelium forms a barrier against the intestinal contents and the wider environment, allowing entry of selected molecules for nutrition and programming of the mucosal immune system, but excluding toxins and most microorganisms. Many receptors and signalling pathways are coupled and implicated in the ep...

journal_title：Current pharmaceutical design

authors： Talero E,Garcia-Maurino S,Motilva V

更新日期：2014-01-01 00:00:00

abstract：BACKGROUND AND OBJECTIVE:Oxidative stress and inflammation are key parameters in developing metabolic disorders. Hence, antioxidant intake might be an appropriate approach. Several studies have evaluated the effect of coenzyme Q10 (CoQ10) supplementation on lipid profile among patients with metabolic diseases, though f...

journal_title：Current pharmaceutical design

authors： Sharifi N,Tabrizi R,Moosazadeh M,Mirhosseini N,Lankarani KB,Akbari M,Chamani M,Kolahdooz F,Asemi Z

更新日期：2018-01-01 00:00:00

abstract：BACKGROUND:Type 1 diabetes is a chronic autoimmune disease featured by insulin deprivation caused by pancreatic β-cell loss, followed by hyperglycaemia. OBJECTIVE:Currently, there is no cure for this disease in clinical treatment, and patients have to accept a lifelong injection of insulin. The exploration of potentia...

journal_title：Current pharmaceutical design

authors： Wang R,Zhou Y,Zhang Y,Li S,Pan R,Zhao Y

更新日期：2020-12-17 00:00:00

abstract：:Inhaled glucocorticoids, also know as corticosteroids (ICS), revolutionized the treatment of asthma by suppressing airways inflammation and ICS therapy now forms the basis of treatment of asthma of all severities. More recently and usually in combination with a long-acting β-agonist (LABA), ICS use has been establishe...

journal_title：Current pharmaceutical design

authors： Adcock IM,Marwick J,Casolari P,Contoli M,Chung KF,Kirkham P,Papi A,Caramori G

更新日期：2010-01-01 00:00:00

abstract：:Most heterosexual women want to reduce the risk of acquiring a sexually transmitted infection; many also want to control their fertility. Several chemical agents have been proposed to dramatically slow the spread of HIV infections. Ideally, vaginal microbicides, with or without contraceptive properties, should be safe...

journal_title：Current pharmaceutical design

authors： Gandour RD

更新日期：2005-01-01 00:00:00

abstract：:Although escape from tumor dormancy has long been recognized as an important problem in the treatment of cancer, the molecular and cellular regulators underlying this transition remain poorly understood. The inability of the cancer cells to induce a complete and successful process of angiogenesis can result in tumor d...

journal_title：Current pharmaceutical design

authors： Shaked Y,McAllister S,Fainaru O,Almog N

更新日期：2014-01-01 00:00:00

abstract：:Histone deacetylases (HDACs), which act on acetylated histones and/or other non-histone protein substrates, represent validated epigenetic targets for the treatment of cancer and other human diseases. The inhibition of HDAC activity was shown to induce cell cycle arrest, differentiation, apoptosis as well as a decreas...

journal_title：Current pharmaceutical design

authors： Kollar J,Frecer V

更新日期：2015-01-01 00:00:00

abstract：:Over the last 15 years, the use of various biological therapies has largely improved the way we manage patients with Inflammatory Bowel Diseases (IBDs). Blockade of cytokine synthesis and/or activity is at the forefront of this new era with the success of inhibitors of tumor necrosis factor (TNF)-α. These therapies ar...

journal_title：Current pharmaceutical design

authors： De Nitto D,Sarra M,Cupi ML,Pallone F,Monteleone G

更新日期：2010-01-01 00:00:00

abstract：BACKGROUND:Absorption windows in particular segments of the small intestine can contribute to the development of orally administered drug formulations and can limit the bioavailability of released compounds. OBJECTIVE:The aim of this study was to evaluate use of wireless capsule enteroscopy regarding the disintegratio...

journal_title：Current pharmaceutical design

authors： Kvetina J,Tacheci I,Nobilis M,Kopacova M,Kunes M,Bures J

更新日期：2017-01-01 00:00:00

abstract：:DAP12 is a novel immunoreceptor tyrosine-based activation motifs (ITAM)-bearing transmembrane adapter molecule. This molecule, together with its partner receptor complex molecules including the killer cell activating receptors (KARs), myeloid DAP12 associating lectin-1 (MDL-1), triggering receptor expressed on myeloid...

journal_title：Current pharmaceutical design

authors： Aoki N,Kimura S,Xing Z

更新日期：2003-01-01 00:00:00

abstract：:We set up two models of gastric bleeding in rats using low-dose aspirin (ASA) and the antiplatelet drug clopidogrel, a P2Y₁₂ receptor antagonist, and examined the effect of antiulcer drugs on gastric bleeding and ulcerogenic responses under such conditions. Under urethane anesthesia, two catheters were inserted into t...

journal_title：Current pharmaceutical design

authors： Takeuchi K,Izuhara C,Takayama S,Momode T,Kojo M,Hara D,Amagase K

更新日期：2014-01-01 00:00:00

abstract：:Unlike other neuroinflammatory disorders, like Parkinson's disease, Huntington's disease and multiple sclerosis, little is still known of the role of the endocannabinoid system in Alzheimer's disease (AD). This is partly due to the poor availability of animal models that are really relevant to the human disease, and t...

journal_title：Current pharmaceutical design

authors： Bisogno T,Di Marzo V

更新日期：2008-01-01 00:00:00

abstract：BACKGROUND:The global burden of gastrointestinal cancers, including colorectal, stomach, and esophageal cancers is rising steadily. Several therapeutic approaches have been considered for the treatment of GI carcinomas. However, none showed to halt or cure the disease. There is a need to develop effective targeted mole...

journal_title：Current pharmaceutical design

authors： Mahmood MQ,Shukla SD,Dua K,Shastri MD

更新日期：2017-01-01 00:00:00

abstract：:Pituitary adenylyl cyclase activating polypeptide (PACAP) is a neuropeptide with great neuroprotective effects and remarkable therapeutic potential. PACAP activates several cellular pathways to exert its protective effects. Emerging evidence shows that PACAP can modify the levels and activity of cell cycle components ...

journal_title：Current pharmaceutical design

authors： Polanco MJ,Pennuto M

更新日期：2018-01-01 00:00:00

abstract：:Prevention, improved screening, and better treatment regimens have improved cancer incidence and mortality in the last decade. Chemoradiation continues to cause high morbidity in patients undergoing treatment. DNA therapeutics have the potential to modify the genes that cause tumor progression in order to produce a re...

journal_title：Current pharmaceutical design

authors： Coppelli FM,Grandis JR

更新日期：2005-01-01 00:00:00

abstract：:Combinations of different technologies are at the heart of the development and implementation of new, innovative processes and approaches for Industry 4.0 in the field of medicinal chemistry and drug discovery. Process intensification and advances in high-throughput synthetic techniques can dramatically improve reacti...

journal_title：Current pharmaceutical design

authors： Tagliapietra S,Binello A,Bucciol F,Trukhan V,Colia M,Cravotto G

更新日期：2020-01-01 00:00:00

abstract：:NAP (davunetide) is an eight amino acid peptide (NAPVSIPQ) that has been shown to provide potent neuroprotection, in vitro and in vivo. In human clinical trials, NAP has been shown to increase memory scores in patients suffering from amnestic mild cognitive impairment, a precursor to Alzheimer's disease and to enhance...

journal_title：Current pharmaceutical design

authors： Gozes I

更新日期：2011-01-01 00:00:00

abstract：:Carbonic anhydrases (CAs, EC 4.2.1.1) are metalloenzymes which catalyze CO(2) hydration to bicarbonate and protons. Five genetically distinct classes are known, which represent an excellent example of convergent evolution. Inhibition of α-CAs from vertebrates, including humans, with sulfonamides was exploited clinical...

journal_title：Current pharmaceutical design

authors： Supuran CT

更新日期：2010-01-01 00:00:00

abstract：:Vasopressin (AVP) secretion and release are regulated by a number of central nervous system sites that receive peripheral signals from the osmoreceptors and baroreceptors. Aim of this paper is to review anatomical pathways and neurotransmitters involved as well as drugs affecting AVP secretion. ...

journal_title：Current pharmaceutical design

authors： Iovino M,Guastamacchia E,Giagulli VA,Licchelli B,Triggiani V

更新日期：2012-01-01 00:00:00